C21-Substituted Neuroactive Steroids for GABA Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for conditions related to brain excitability, such as catamenial epilepsy, premenstrual syndrome, and postnatal depression, are not consistently effective, and there is a need for improved neuroactive steroids that can modulate GABA receptors to address these conditions.
Innovation Solution
Development of C21-substituted neuroactive steroids that act as GABA modulators, designed to induce sedation and anesthesia, and treat CNS-related disorders by administering compounds of specific formulas, including Formula (I) and their pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments (barbiturates, benzodiazepines) are used to modulate GABA receptors, then brain excitability can be regulated, but therapeutic effectiveness is not consistent and side effects occur
Solution Approach 1:
The patent modifies the chemical structure of neuroactive steroids by changing parameters such as substituting C21 hydrogen with various functional groups (carboxyl, hydroxyl, amino, carbonyl) and adjusting stereochemistry at C21 position. These structural parameter changes aim to improve therapeutic effectiveness and reduce side effects by creating compounds with optimized binding affinity and selectivity for GABA-A receptor subtypes.
Solution Approach 2:
The invention creates composite molecular structures by combining the core neuroactive steroid framework with various functional groups and substituents (e.g., aryl, heteroaryl, alkyl groups at C21 position). This composite approach allows integration of multiple pharmacological properties into single molecules that can selectively modulate different GABA-A receptor subtypes while minimizing adverse effects.
2Reliability
If neuroactive steroids are developed with improved binding affinity for GABA receptors, then therapeutic efficacy increases, but molecular complexity increases
Solution Approach 1:
The patent applies local quality modification by introducing functional groups and substituents at specific locations (C21 position) of the neuroactive steroid molecule. This localized modification strategy improves binding affinity and selectivity without requiring complex changes throughout the entire molecular structure, thus maintaining reasonable molecular simplicity while enhancing therapeutic efficacy.
3Speed
If rapid onset of sedation and anesthesia is achieved, then therapeutic response time decreases, but control precision becomes more difficult
Solution Approach 1:
The invention creates dynamic pharmacological profiles by designing neuroactive steroid compounds that can be administered at different doses and formulations (oral, intravenous, intramuscular) to achieve rapid onset when needed while allowing for controlled duration and intensity. The flexible dosing regimens and pharmacokinetic properties enable rapid therapeutic response with maintainable control through dose adjustment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively modulate GABA receptors, providing therapeutic benefits for conditions like epilepsy, depression, and other CNS disorders, with potential for rapid onset of sedation and anesthesia.
Implementation Method 1
The compounds effectively modulate GABA receptors, providing therapeutic benefits for conditions like epilepsy, depression, and other CNS disorders
Implementation Method 2
GABA regulates the excitability of individual neurons by regulating the conductance of chloride ions across the neuronal membrane
Implementation Method 3
GABA has a profound influence on overall brain excitability because up to 40% of the neurons in the brain utilize GABA as a neurotransmitter
Implementation Method 4
An intracellular increase in the levels of this anion causes hyperpolarization of the transmembrane potential, rendering the neuron less susceptible to excitatory inputs
Data Source
AI summary
Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein, R1, R2a, R2b, R3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.